bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags sequence	text stringlengths 5 72.4k	tokens sequence	types sequence
Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm	DerUnfallchirurg.71000694.ger.abstr_task0	Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .	[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]	[ "umlsterm" ]
Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm	DerUnfallchirurg.71000694.ger.abstr_task1	Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please typing these entity words according to sentence: Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .	[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]	[ "umlsterm" ]
Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten	DerUnfallchirurg.71000694.ger.abstr_task2	Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .	[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]	[ "umlsterm" ]
transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm	DerRadiologe.70370336.eng.abstr_task0	Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .	[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]	[ "umlsterm" ]
transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm	DerRadiologe.70370336.eng.abstr_task1	Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please typing these entity words according to sentence: transfer, safety, interaction, teleradiology, selection Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .	[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]	[ "umlsterm" ]
transfer, safety, interaction, teleradiology, selection	DerRadiologe.70370336.eng.abstr_task2	Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .	[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]	[ "umlsterm" ]
Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm	DerOpthalmologe.70940665.ger.abstr_task0	Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?	[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]	[ "umlsterm" ]
Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm	DerOpthalmologe.70940665.ger.abstr_task1	Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please typing these entity words according to sentence: Drucksenkung, Glaukomaugen Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?	[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]	[ "umlsterm" ]
Drucksenkung, Glaukomaugen	DerOpthalmologe.70940665.ger.abstr_task2	Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?	[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]	[ "umlsterm" ]
man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm	MundKieferGesichtschirurgie.80020279.eng.abstr_task0	Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .	[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]	[ "umlsterm" ]
man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm	MundKieferGesichtschirurgie.80020279.eng.abstr_task1	Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please typing these entity words according to sentence: man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .	[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]	[ "umlsterm" ]
man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy	MundKieferGesichtschirurgie.80020279.eng.abstr_task2	Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]	A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .	[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]	[ "umlsterm" ]
Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND	Fosfomycin_ddi_task0	Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: BRAND, DRUG	[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.	[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]	[ "DRUG", "BRAND" ]
Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND	Fosfomycin_ddi_task1	Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please typing these entity words according to sentence: Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL Options: BRAND, DRUG	[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.	[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]	[ "DRUG", "BRAND" ]
Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL	Fosfomycin_ddi_task2	Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entity words from the input sentence	[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]	Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.	[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]	[ "DRUG", "BRAND" ]
I - DOX is a chemical, TTR is a protein, FAP is a disease	1.0alpha7.train.194_task0	Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: disease, chemical, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]	The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.	[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]	[ "chemical", "protein", "disease" ]
I - DOX is a chemical, TTR is a protein, FAP is a disease	1.0alpha7.train.194_task1	Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please typing these entity words according to sentence: I - DOX, TTR, FAP Options: disease, chemical, protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]	The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.	[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]	[ "chemical", "protein", "disease" ]
I - DOX, TTR, FAP	1.0alpha7.train.194_task2	Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]	The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.	[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]	[ "chemical", "protein", "disease" ]
prostaglandin is a CHEMICAL	12713596_task0	Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.	[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
prostaglandin is a CHEMICAL	12713596_task1	Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please typing these entity words according to sentence: prostaglandin Options: CHEMICAL	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.	[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
prostaglandin	12713596_task2	Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entity words from the input sentence	[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.	[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein	9032271_task0	Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]	Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.	[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]	[ "Entity", "Protein" ]
I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein	9032271_task1	Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please typing these entity words according to sentence: I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]	Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.	[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]	[ "Entity", "Protein" ]
I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon	9032271_task2	Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]	Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.	[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]	[ "Entity", "Protein" ]
Toxicities , including thromboembolism is an outcome, overall survival is an outcome	892_task0	Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome	[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]	Toxicities , including thromboembolism , and overall survival were similar .	[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]	[ "outcome" ]
Toxicities , including thromboembolism is an outcome, overall survival is an outcome	892_task1	Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please typing these entity words according to sentence: Toxicities , including thromboembolism, overall survival Options: outcome	[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]	Toxicities , including thromboembolism , and overall survival were similar .	[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]	[ "outcome" ]
Toxicities , including thromboembolism, overall survival	892_task2	Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entity words from the input sentence	[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]	Toxicities , including thromboembolism , and overall survival were similar .	[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]	[ "outcome" ]
hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control	17841_task0	Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .	[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]	[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]
hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control	17841_task1	Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please typing these entity words according to sentence: hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .	[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]	[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]
hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet	17841_task2	Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .	[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]	[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]
CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene	225_task0	Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.	[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]	[ "Gene" ]
CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene	225_task1	Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please typing these entity words according to sentence: CHH, CHH, CHH, CHH, CHH Options: Gene	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.	[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]	[ "Gene" ]
CHH, CHH, CHH, CHH, CHH	225_task2	Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.	[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]	[ "Gene" ]
urologic surgery is a Procedure	NCT02805504_inc_task0	Sentence: Patients undergoing urologic surgery. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Procedure	[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	Patients undergoing urologic surgery.	[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]	[ "Procedure" ]
urologic surgery is a Procedure	NCT02805504_inc_task1	Sentence: Patients undergoing urologic surgery. Instructions: please typing these entity words according to sentence: urologic surgery Options: Procedure	[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	Patients undergoing urologic surgery.	[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]	[ "Procedure" ]
urologic surgery	NCT02805504_inc_task2	Sentence: Patients undergoing urologic surgery. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]	Patients undergoing urologic surgery.	[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]	[ "Procedure" ]
Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm	Reproduktionsmedizin.90150159.ger.abstr_task0	Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .	[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]	[ "umlsterm" ]
Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm	Reproduktionsmedizin.90150159.ger.abstr_task1	Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please typing these entity words according to sentence: Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .	[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]	[ "umlsterm" ]
Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen	Reproduktionsmedizin.90150159.ger.abstr_task2	Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .	[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]	[ "umlsterm" ]
neurotoxicity is a ADVERSE	example-381_task0	Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]	Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.	[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]	[ "ADVERSE" ]
neurotoxicity is a ADVERSE	example-381_task1	Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please typing these entity words according to sentence: neurotoxicity Options: ADVERSE	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]	Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.	[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]	[ "ADVERSE" ]
neurotoxicity	example-381_task2	Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]	Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.	[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]	[ "ADVERSE" ]
alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay	1.0alpha7.train.1055_task0	Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: assay, DNA, reagent, protein	[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).	[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]	[ "reagent", "DNA", "assay", "protein" ]
alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay	1.0alpha7.train.1055_task1	Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please typing these entity words according to sentence: alpha - UBF antibody, UBF, rDNA, FISH Options: assay, DNA, reagent, protein	[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).	[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]	[ "reagent", "DNA", "assay", "protein" ]
alpha - UBF antibody, UBF, rDNA, FISH	1.0alpha7.train.1055_task2	Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).	[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]	[ "reagent", "DNA", "assay", "protein" ]
Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region	62654_task0	Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, DNA_domain_or_region	[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]	Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.	[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]	[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]
Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region	62654_task1	Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please typing these entity words according to sentence: Sp family members, promoter proximal repeat, HTLV - I enhancer Options: protein_family_or_group, DNA_domain_or_region	[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]	Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.	[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]	[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]
Sp family members, promoter proximal repeat, HTLV - I enhancer	62654_task2	Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entity words from the input sentence	[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]	Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.	[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]	[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]

Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm

DerUnfallchirurg.71000694.ger.abstr_task0

Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .

[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]

[ "umlsterm" ]

Pionierzeit is an umlsterm, Replantation is an umlsterm, Extremitaet is an umlsterm, Schmerzen is an umlsterm, Replantation is an umlsterm, Unfallmechanismus is an umlsterm, Replantation is an umlsterm, Patienten is an umlsterm

DerUnfallchirurg.71000694.ger.abstr_task1

Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please typing these entity words according to sentence: Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .

[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]

[ "umlsterm" ]

Pionierzeit, Replantation, Extremitaet, Schmerzen, Replantation, Unfallmechanismus, Replantation, Patienten

DerUnfallchirurg.71000694.ger.abstr_task2

Sentence: In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

In der Pionierzeit der Replantationschirurgie wurde der Erfolg alleine an der Vitalitaet des Replantates ( Ueberlebensrate ) gemessen . Spricht man heute von einer erfolgreichen Replantation muessen neben der Vitalitaet zusaetzliche Kriterien wie , ein geringes Replantationsrisiko , eine funktionelle Extremitaet " " nach den Kriterien von [ 18 ] , keine oder nur geringe Schmerzen im Replantationsgebiet , ein befriedigendes aesthetisches Ergebnis und eine akzeptable Dauer der sozialen und beruflichen Wiedereingliederung erfuellt sein . Die erfolgreiche Replantation erfordert ein Gesamtkonzept , welches beinhaltet , eine exakte Beschreibung der vorliegenden Amputationsverletzung hinsichtlich Ausmass ( total/subtotal Lokalisation und Unfallmechanismus , ) , die Kenntnis der aktuellen Replantationsindikationen , und die Auswahl des fuer die Replantation geeigneten Patienten .

[ "In", "der", "Pionierzeit", "der", "Replantationschirurgie", "wurde", "der", "Erfolg", "alleine", "an", "der", "Vitalitaet", "des", "Replantates", "(", "Ueberlebensrate", ")", "gemessen", ".", "Spricht", "man", "heute", "von", "einer", "erfolgreichen", "Replantation", "muessen", "neben", "der", "Vitalitaet", "zusaetzliche", "Kriterien", "wie", ",", "ein", "geringes", "Replantationsrisiko", ",", "eine", "funktionelle", "Extremitaet", "\"", "\"", "nach", "den", "Kriterien", "von", "[", "18", "]", ",", "keine", "oder", "nur", "geringe", "Schmerzen", "im", "Replantationsgebiet", ",", "ein", "befriedigendes", "aesthetisches", "Ergebnis", "und", "eine", "akzeptable", "Dauer", "der", "sozialen", "und", "beruflichen", "Wiedereingliederung", "erfuellt", "sein", ".", "Die", "erfolgreiche", "Replantation", "erfordert", "ein", "Gesamtkonzept", ",", "welches", "beinhaltet", ",", "eine", "exakte", "Beschreibung", "der", "vorliegenden", "Amputationsverletzung", "hinsichtlich", "Ausmass", "(", "total", "/", "subtotal", "Lokalisation", "und", "Unfallmechanismus", ",", ")", ",", "die", "Kenntnis", "der", "aktuellen", "Replantationsindikationen", ",", "und", "die", "Auswahl", "des", "fuer", "die", "Replantation", "geeigneten", "Patienten", "." ]

[ "umlsterm" ]

transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm

DerRadiologe.70370336.eng.abstr_task0

Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .

[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]

[ "umlsterm" ]

transfer is an umlsterm, safety is an umlsterm, interaction is an umlsterm, teleradiology is an umlsterm, selection is an umlsterm

DerRadiologe.70370336.eng.abstr_task1

Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please typing these entity words according to sentence: transfer, safety, interaction, teleradiology, selection Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .

[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]

[ "umlsterm" ]

transfer, safety, interaction, teleradiology, selection

DerRadiologe.70370336.eng.abstr_task2

Sentence: Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Teleradiologysystems can differ considerably in their features . The most important differences lie in the mode of image data acquisition , data transfer , data safety aspects and the possibilities of interaction between seperate teleradiology units . A selection of commercially available teleradiologysystems is presented and compared .

[ "Teleradiologysystems", "can", "differ", "considerably", "in", "their", "features", ".", "The", "most", "important", "differences", "lie", "in", "the", "mode", "of", "image", "data", "acquisition", ",", "data", "transfer", ",", "data", "safety", "aspects", "and", "the", "possibilities", "of", "interaction", "between", "seperate", "teleradiology", "units", ".", "A", "selection", "of", "commercially", "available", "teleradiologysystems", "is", "presented", "and", "compared", "." ]

[ "umlsterm" ]

Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm

DerOpthalmologe.70940665.ger.abstr_task0

Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?

[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]

[ "umlsterm" ]

Drucksenkung is an umlsterm, Glaukomaugen is an umlsterm

DerOpthalmologe.70940665.ger.abstr_task1

Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please typing these entity words according to sentence: Drucksenkung, Glaukomaugen Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?

[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]

[ "umlsterm" ]

Drucksenkung, Glaukomaugen

DerOpthalmologe.70940665.ger.abstr_task2

Sentence: Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ? Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Problemstellung : Wie weit ist eine Drucksenkung bei Glaukomaugen durch punktfoermige Ablation des Trabekelwerks mit dem Excimerlaser moeglich ?

[ "Problemstellung", ":", "Wie", "weit", "ist", "eine", "Drucksenkung", "bei", "Glaukomaugen", "durch", "punktfoermige", "Ablation", "des", "Trabekelwerks", "mit", "dem", "Excimerlaser", "moeglich", "?" ]

[ "umlsterm" ]

man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm

MundKieferGesichtschirurgie.80020279.eng.abstr_task0

Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .

[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]

[ "umlsterm" ]

man is an umlsterm, giant - cell is an umlsterm, tumor is an umlsterm, right is an umlsterm, temporomandibular joint is an umlsterm, growth is an umlsterm, treatment is an umlsterm, endotracheal anesthesia is an umlsterm, recurrence is an umlsterm, Differential diagnosis is an umlsterm, therapy is an umlsterm

MundKieferGesichtschirurgie.80020279.eng.abstr_task1

Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please typing these entity words according to sentence: man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .

[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]

[ "umlsterm" ]

man, giant - cell, tumor, right, temporomandibular joint, growth, treatment, endotracheal anesthesia, recurrence, Differential diagnosis, therapy

MundKieferGesichtschirurgie.80020279.eng.abstr_task2

Sentence: A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O" ]

A 63-year-old man is presented in whom a tenosynovial giant-cell tumor destroyed the right temporomandibular joint and fossa and showed extensive intracranial growth . Because of uncharacteristic complaints , a symptomatic treatment was performed elsewhere . The lesion was finally resected under endotracheal anesthesia . After 20 months free of recurrence the patient's outcome is very satisfying . Differential diagnosis and therapy are discussed .

[ "A", "63-year", "-", "old", "man", "is", "presented", "in", "whom", "a", "tenosynovial", "giant", "-", "cell", "tumor", "destroyed", "the", "right", "temporomandibular", "joint", "and", "fossa", "and", "showed", "extensive", "intracranial", "growth", ".", "Because", "of", "uncharacteristic", "complaints", ",", "a", "symptomatic", "treatment", "was", "performed", "elsewhere", ".", "The", "lesion", "was", "finally", "resected", "under", "endotracheal", "anesthesia", ".", "After", "20", "months", "free", "of", "recurrence", "the", "patient", "'s", "outcome", "is", "very", "satisfying", ".", "Differential", "diagnosis", "and", "therapy", "are", "discussed", "." ]

[ "umlsterm" ]

Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND

Fosfomycin_ddi_task0

Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: BRAND, DRUG

[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]

Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.

[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]

[ "DRUG", "BRAND" ]

Metoclopramide is a DRUG, MONUROL is a BRAND, metoclopramide is a DRUG, fosfomycin is a DRUG, Cimetidine is a DRUG, Cimetidine is a DRUG, fosfomycin is a DRUG, MONUROL is a BRAND

Fosfomycin_ddi_task1

Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please typing these entity words according to sentence: Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL Options: BRAND, DRUG

[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]

Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.

[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]

[ "DRUG", "BRAND" ]

Metoclopramide, MONUROL, metoclopramide, fosfomycin, Cimetidine, Cimetidine, fosfomycin, MONUROL

Fosfomycin_ddi_task2

Sentence: Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL. Instructions: please extract entity words from the input sentence

[ "B-DRUG", "O", "O", "O", "O", "B-BRAND", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "B-BRAND", "O" ]

Metoclopramide: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin. Other drugs that increase gastrointestinal motility may produce similar effects. Cimetidine: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.

[ "Metoclopramide", ":", "When", "coadministered", "with", "MONUROL", ",", "metoclopramide", ",", "a", "drug", "which", "increases", "gastrointestinal", "motility", ",", "lowers", "the", "serum", "concentration", "and", "urinary", "excretion", "of", "fosfomycin", ".", "Other", "drugs", "that", "increase", "gastrointestinal", "motility", "may", "produce", "similar", "effects", ".", "Cimetidine", ":", "Cimetidine", "does", "not", "affect", "the", "pharmacokinetics", "of", "fosfomycin", "when", "coadministered", "with", "MONUROL", "." ]

[ "DRUG", "BRAND" ]

I - DOX is a chemical, TTR is a protein, FAP is a disease

1.0alpha7.train.194_task0

Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: disease, chemical, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]

The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.

[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]

[ "chemical", "protein", "disease" ]

I - DOX is a chemical, TTR is a protein, FAP is a disease

1.0alpha7.train.194_task1

Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please typing these entity words according to sentence: I - DOX, TTR, FAP Options: disease, chemical, protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]

The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.

[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]

[ "chemical", "protein", "disease" ]

I - DOX, TTR, FAP

1.0alpha7.train.194_task2

Sentence: The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "I-chemical", "I-chemical", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "B-disease", "O" ]

The data presented in this study clearly show that I-DOX binds specifically to TTR amyloid fibrils in tissues from patients with FAP.

[ "The", "data", "presented", "in", "this", "study", "clearly", "show", "that", "I", "-", "DOX", "binds", "specifically", "to", "TTR", "amyloid", "fibrils", "in", "tissues", "from", "patients", "with", "FAP", "." ]

[ "chemical", "protein", "disease" ]

prostaglandin is a CHEMICAL

12713596_task0

Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.

[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

prostaglandin is a CHEMICAL

12713596_task1

Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please typing these entity words according to sentence: prostaglandin Options: CHEMICAL

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.

[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

prostaglandin

12713596_task2

Sentence: Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair. Instructions: please extract entity words from the input sentence

[ "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.

[ "Cyclooxygenase-1-coupled", "prostaglandin", "biosynthesis", "constitutes", "an", "essential", "prerequisite", "for", "skin", "repair", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein

9032271_task0

Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]

Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.

[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]

[ "Entity", "Protein" ]

I kappaB alpha is a Protein, serines 32 and 36 is a Entity, I kappaB alpha is a Protein, p50 is a Protein, relA is a Protein, I kappaB alpha is a Protein, I kappaB alpha is a Protein, Tax is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein, I kappaB alpha is a Protein, I kappaB beta is a Protein, I kappaB epsilon is a Protein

9032271_task1

Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please typing these entity words according to sentence: I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]

Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.

[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]

[ "Entity", "Protein" ]

I kappaB alpha, serines 32 and 36, I kappaB alpha, p50, relA, I kappaB alpha, I kappaB alpha, Tax, I kappaB beta, I kappaB epsilon, I kappaB alpha, I kappaB beta, I kappaB epsilon

9032271_task2

Sentence: Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O" ]

Characterization of a mutant cell line that does not activate NF-kappaB in response to multiple stimuli. Numerous genes required during the immune or inflammation response as well as the adhesion process are regulated by nuclear factor kappaB (NF-kappaB). Associated with its inhibitor, I kappaB, NF-kappaB resides as an inactive form in the cytoplasm. Upon stimulation by various agents, I kappaB is proteolyzed and NF-kappaB translocates to the nucleus, where it activates its target genes. The transduction pathways that lead to I kappaB inactivation remain poorly understood. In this study, we have characterized a cellular mutant, the 70/Z3-derived 1.3E2 murine pre-B cell line, that does not activate NF-kappaB in response to several stimuli. We demonstrate that upon stimulation by lipopolysaccharide, Taxol, phorbol myristate acetate, interleukin-1, or double-stranded RNA, I kappaB alpha is not degraded, as a result of an absence of induced phosphorylation on serines 32 and 36. Neither a mutation in I kappaB alpha nor a mutation in p50 or relA, the two major subunits of NF-kappaB in this cell line, accounts for this phosphorylation defect. As well as culminating in the inducible phosphorylation of I kappaB alpha on serines 32 and 36, all the stimuli that are inactive on 1.3E2 cells exhibit a sensitivity to the antioxidant pyrrolidine dithiocarbamate (PDTC). In contrast, stimuli such as hyperosmotic shock or phosphatase inhibitors, which use PDTC-insensitive pathways, induce I kappaB alpha degradation in 1.3E2. Analysis of the redox status of 1.3E2 does not reveal any difference from wild-type 70Z/3. We also report that the human T-cell leukemia virus type 1 (HTLV-1)-derived Tax trans-activator induces NF-kappaB activity in 1.3E2, suggesting that this viral protein does not operate via the defective pathway. Finally, we show that two other I kappaB molecules, I kappaB beta and the recently identified I kappaB epsilon, are not degraded in the 1.3E2 cell line following stimulation. Our results demonstrate that 1.3E2 is a cellular transduction mutant exhibiting a defect in a step that is required by several different stimuli to activate NF-kappaB. In addition, this analysis suggests a common step in the signaling pathways that trigger I kappaB alpha, I kappaB beta, and I kappaB epsilon degradation.

[ "Characterization", "of", "a", "mutant", "cell", "line", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "multiple", "stimuli", ".", "\n", "Numerous", "genes", "required", "during", "the", "immune", "or", "inflammation", "response", "as", "well", "as", "the", "adhesion", "process", "are", "regulated", "by", "nuclear", "factor", "kappaB", "(", "NF", "-", "kappaB", ")", ".", "Associated", "with", "its", "inhibitor", ",", "I", "kappaB", ",", "NF", "-", "kappaB", "resides", "as", "an", "inactive", "form", "in", "the", "cytoplasm", ".", "Upon", "stimulation", "by", "various", "agents", ",", "I", "kappaB", "is", "proteolyzed", "and", "NF", "-", "kappaB", "translocates", "to", "the", "nucleus", ",", "where", "it", "activates", "its", "target", "genes", ".", "The", "transduction", "pathways", "that", "lead", "to", "I", "kappaB", "inactivation", "remain", "poorly", "understood", ".", "In", "this", "study", ",", "we", "have", "characterized", "a", "cellular", "mutant", ",", "the", "70", "/", "Z3-derived", "1.3E2", "murine", "pre", "-", "B", "cell", "line", ",", "that", "does", "not", "activate", "NF", "-", "kappaB", "in", "response", "to", "several", "stimuli", ".", "We", "demonstrate", "that", "upon", "stimulation", "by", "lipopolysaccharide", ",", "Taxol", ",", "phorbol", "myristate", "acetate", ",", "interleukin-1", ",", "or", "double", "-", "stranded", "RNA", ",", "I", "kappaB", "alpha", "is", "not", "degraded", ",", "as", "a", "result", "of", "an", "absence", "of", "induced", "phosphorylation", "on", "serines", "32", "and", "36", ".", "Neither", "a", "mutation", "in", "I", "kappaB", "alpha", "nor", "a", "mutation", "in", "p50", "or", "relA", ",", "the", "two", "major", "subunits", "of", "NF", "-", "kappaB", "in", "this", "cell", "line", ",", "accounts", "for", "this", "phosphorylation", "defect", ".", "As", "well", "as", "culminating", "in", "the", "inducible", "phosphorylation", "of", "I", "kappaB", "alpha", "on", "serines", "32", "and", "36", ",", "all", "the", "stimuli", "that", "are", "inactive", "on", "1.3E2", "cells", "exhibit", "a", "sensitivity", "to", "the", "antioxidant", "pyrrolidine", "dithiocarbamate", "(", "PDTC", ")", ".", "In", "contrast", ",", "stimuli", "such", "as", "hyperosmotic", "shock", "or", "phosphatase", "inhibitors", ",", "which", "use", "PDTC", "-", "insensitive", "pathways", ",", "induce", "I", "kappaB", "alpha", "degradation", "in", "1.3E2", ".", "Analysis", "of", "the", "redox", "status", "of", "1.3E2", "does", "not", "reveal", "any", "difference", "from", "wild", "-", "type", "70Z/3", ".", "We", "also", "report", "that", "the", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-derived", "Tax", "trans", "-", "activator", "induces", "NF", "-", "kappaB", "activity", "in", "1.3E2", ",", "suggesting", "that", "this", "viral", "protein", "does", "not", "operate", "via", "the", "defective", "pathway", ".", "Finally", ",", "we", "show", "that", "two", "other", "I", "kappaB", "molecules", ",", "I", "kappaB", "beta", "and", "the", "recently", "identified", "I", "kappaB", "epsilon", ",", "are", "not", "degraded", "in", "the", "1.3E2", "cell", "line", "following", "stimulation", ".", "Our", "results", "demonstrate", "that", "1.3E2", "is", "a", "cellular", "transduction", "mutant", "exhibiting", "a", "defect", "in", "a", "step", "that", "is", "required", "by", "several", "different", "stimuli", "to", "activate", "NF", "-", "kappaB.", "In", "addition", ",", "this", "analysis", "suggests", "a", "common", "step", "in", "the", "signaling", "pathways", "that", "trigger", "I", "kappaB", "alpha", ",", "I", "kappaB", "beta", ",", "and", "I", "kappaB", "epsilon", "degradation", "." ]

[ "Entity", "Protein" ]

Toxicities , including thromboembolism is an outcome, overall survival is an outcome

892_task0

Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: outcome

[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]

Toxicities , including thromboembolism , and overall survival were similar .

[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]

[ "outcome" ]

Toxicities , including thromboembolism is an outcome, overall survival is an outcome

892_task1

Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please typing these entity words according to sentence: Toxicities , including thromboembolism, overall survival Options: outcome

[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]

Toxicities , including thromboembolism , and overall survival were similar .

[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]

[ "outcome" ]

Toxicities , including thromboembolism, overall survival

892_task2

Sentence: Toxicities , including thromboembolism , and overall survival were similar . Instructions: please extract entity words from the input sentence

[ "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O", "O", "B-outcome", "I-outcome", "O", "O", "O" ]

Toxicities , including thromboembolism , and overall survival were similar .

[ "Toxicities", ",", "including", "thromboembolism", ",", "and", "overall", "survival", "were", "similar", "." ]

[ "outcome" ]

hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control

17841_task0

Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .

[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]

[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]

hypertension is a Participant_Condition, reduced sodium intake is a Intervention_Physical, Dietary Approaches to Stop Hypertension ( DASH ) diet is a Intervention_Other, blood pressure ( BP ) is a Outcome_Physical, Adults is a Participant_Age, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg is a Participant_Condition, DASH diet is a Intervention_Educational, typical American ( control ) diet is a Intervention_Control, BP control is a Outcome_Physical, increased BP control is a Outcome_Physical, maximum BP control rate is a Outcome_Physical, DASH / lower sodium diet is a Intervention_Educational, control / lower sodium diet is a Intervention_Control

17841_task1

Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please typing these entity words according to sentence: hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet Options: Intervention_Physical, Participant_Condition, Intervention_Control, Intervention_Educational, Intervention_Other, Participant_Age, Outcome_Physical

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .

[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]

[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]

hypertension, reduced sodium intake, Dietary Approaches to Stop Hypertension ( DASH ) diet, blood pressure ( BP ), Adults, systolic BP 120 - 159 mm Hg and diastolic BP 80 - 95 mm Hg, DASH diet, typical American ( control ) diet, BP control, increased BP control, maximum BP control rate, DASH / lower sodium diet, control / lower sodium diet

17841_task2

Sentence: Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "I-Intervention_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "B-Participant_Age", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of the dietary approaches to stop hypertension diet and reduced sodium intake on blood pressure control . The authors hypothesized that the Dietary Approaches to Stop Hypertension ( DASH ) diet and reduced sodium intake would control stage 1 hypertension and reduce high-normal blood pressure ( BP ) to optimal levels . Adults with systolic BP 120-159 mm Hg and diastolic BP 80-95 mm Hg were randomly assigned to receive the DASH diet or a typical American ( control ) diet , consuming three different sodium intakes ( higher=142 mmol/d , intermediate=107 mmol/d , and lower=65 mmol/d ) for 30 days each . BP control was defined as systolic BP < 140 mm Hg and diastolic BP < 90 mm Hg . Among subjects with hypertension at baseline , at higher sodium intake the DASH diet increased BP control two-fold over control ( 63 % vs. 32 % ; 95 % confidence interval , 1.4-2.9 ) . Reducing sodium intake in the control diet group increased BP control 2.3-fold ( 74 % vs. 32 % ; 95 % confidence interval , 1.7-3.2 ) . The maximum BP control rate ( 84 % ) was achieved with the DASH/lower sodium diet . BP became normal or optimal in 71 % of persons consuming the control/lower sodium diet and 77 % of persons consuming the DASH/lower sodium diet . Both the DASH diet and reduced sodium intake improved BP control .

[ "Effect", "of", "the", "dietary", "approaches", "to", "stop", "hypertension", "diet", "and", "reduced", "sodium", "intake", "on", "blood", "pressure", "control", ".", "The", "authors", "hypothesized", "that", "the", "Dietary", "Approaches", "to", "Stop", "Hypertension", "(", "DASH", ")", "diet", "and", "reduced", "sodium", "intake", "would", "control", "stage", "1", "hypertension", "and", "reduce", "high", "-", "normal", "blood", "pressure", "(", "BP", ")", "to", "optimal", "levels", ".", "Adults", "with", "systolic", "BP", "120", "-", "159", "mm", "Hg", "and", "diastolic", "BP", "80", "-", "95", "mm", "Hg", "were", "randomly", "assigned", "to", "receive", "the", "DASH", "diet", "or", "a", "typical", "American", "(", "control", ")", "diet", ",", "consuming", "three", "different", "sodium", "intakes", "(", "higher=142", "mmol", "/", "d", ",", "intermediate=107", "mmol", "/", "d", ",", "and", "lower=65", "mmol", "/", "d", ")", "for", "30", "days", "each", ".", "BP", "control", "was", "defined", "as", "systolic", "BP", "<", "140", "mm", "Hg", "and", "diastolic", "BP", "<", "90", "mm", "Hg", ".", "Among", "subjects", "with", "hypertension", "at", "baseline", ",", "at", "higher", "sodium", "intake", "the", "DASH", "diet", "increased", "BP", "control", "two", "-", "fold", "over", "control", "(", "63", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.4", "-", "2.9", ")", ".", "Reducing", "sodium", "intake", "in", "the", "control", "diet", "group", "increased", "BP", "control", "2.3-fold", "(", "74", "%", "vs", ".", "32", "%", ";", "95", "%", "confidence", "interval", ",", "1.7", "-", "3.2", ")", ".", "The", "maximum", "BP", "control", "rate", "(", "84", "%", ")", "was", "achieved", "with", "the", "DASH", "/", "lower", "sodium", "diet", ".", "BP", "became", "normal", "or", "optimal", "in", "71", "%", "of", "persons", "consuming", "the", "control", "/", "lower", "sodium", "diet", "and", "77", "%", "of", "persons", "consuming", "the", "DASH", "/", "lower", "sodium", "diet", ".", "Both", "the", "DASH", "diet", "and", "reduced", "sodium", "intake", "improved", "BP", "control", "." ]

[ "Participant_Condition", "Intervention_Other", "Intervention_Control", "Outcome_Physical", "Intervention_Educational", "Intervention_Physical", "Participant_Age" ]

CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene

225_task0

Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.

[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]

[ "Gene" ]

CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene, CHH is a Gene

225_task1

Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please typing these entity words according to sentence: CHH, CHH, CHH, CHH, CHH Options: Gene

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.

[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]

[ "Gene" ]

CHH, CHH, CHH, CHH, CHH

225_task2

Sentence: High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

High-resolution linkage-disequilibrium mapping of the cartilage-hair hypoplasia gene. We recently assigned the gene for an autosomal recessive skeletal dysplasia, cartilage-hair hypoplasia (CHH), to 9p21-p13 in Finnish and Amish families. An association was observed between CHH and alleles at D9S163 in both family series, suggesting that these loci are in linkage disequilibrium and close to each other. Here we extended these studies by exploiting the linkage-disequilibrium information that can be obtained from families with a single affected child, and we studied 66 Finnish CHH families with seven microsatellite markers. The analysis based on the Luria and Delbrück (1943) method and adapted to the study of human founder populations suggests that the distance between CHH and D9S163 is approximately 0.3 cM. An eight-point linkage analysis modified to take advantage of all possible information in 15 Finnish and 17 Amish families was capable of narrowing the likely location of CHH to within an interval of 1.7 cM on a male map. The peak lod score of 54.92 was attained 0.03 and 0.1 cM proximal to D9S163 on the male and female maps, respectively. These results confirm the power of genetic resolution, that lies in the study of linkage disequilibrium in well-defined founder populations with one major ancestral disease mutation.

[ "High", "-", "resolution", "linkage", "-", "disequilibrium", "mapping", "of", "the", "cartilage", "-", "hair", "hypoplasia", "gene", ".", "We", "recently", "assigned", "the", "gene", "for", "an", "autosomal", "recessive", "skeletal", "dysplasia", ",", "cartilage", "-", "hair", "hypoplasia", "(", "CHH", ")", ",", "to", "9p21-p13", "in", "Finnish", "and", "Amish", "families", ".", "An", "association", "was", "observed", "between", "CHH", "and", "alleles", "at", "D9S163", "in", "both", "family", "series", ",", "suggesting", "that", "these", "loci", "are", "in", "linkage", "disequilibrium", "and", "close", "to", "each", "other", ".", "Here", "we", "extended", "these", "studies", "by", "exploiting", "the", "linkage", "-", "disequilibrium", "information", "that", "can", "be", "obtained", "from", "families", "with", "a", "single", "affected", "child", ",", "and", "we", "studied", "66", "Finnish", "CHH", "families", "with", "seven", "microsatellite", "markers", ".", "The", "analysis", "based", "on", "the", "Luria", "and", "Delbrück", "(", "1943", ")", "method", "and", "adapted", "to", "the", "study", "of", "human", "founder", "populations", "suggests", "that", "the", "distance", "between", "CHH", "and", "D9S163", "is", "approximately", "0.3", "cM.", "An", "eight", "-", "point", "linkage", "analysis", "modified", "to", "take", "advantage", "of", "all", "possible", "information", "in", "15", "Finnish", "and", "17", "Amish", "families", "was", "capable", "of", "narrowing", "the", "likely", "location", "of", "CHH", "to", "within", "an", "interval", "of", "1.7", "cM", "on", "a", "male", "map", ".", "The", "peak", "lod", "score", "of", "54.92", "was", "attained", "0.03", "and", "0.1", "cM", "proximal", "to", "D9S163", "on", "the", "male", "and", "female", "maps", ",", "respectively", ".", "These", "results", "confirm", "the", "power", "of", "genetic", "resolution", ",", "that", "lies", "in", "the", "study", "of", "linkage", "disequilibrium", "in", "well", "-", "defined", "founder", "populations", "with", "one", "major", "ancestral", "disease", "mutation", ".", "\n" ]

[ "Gene" ]

urologic surgery is a Procedure

NCT02805504_inc_task0

Sentence: Patients undergoing urologic surgery. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Procedure

[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

Patients undergoing urologic surgery.

[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]

[ "Procedure" ]

urologic surgery is a Procedure

NCT02805504_inc_task1

Sentence: Patients undergoing urologic surgery. Instructions: please typing these entity words according to sentence: urologic surgery Options: Procedure

[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

Patients undergoing urologic surgery.

[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]

[ "Procedure" ]

urologic surgery

NCT02805504_inc_task2

Sentence: Patients undergoing urologic surgery. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Procedure", "I-Procedure", "O", "O" ]

Patients undergoing urologic surgery.

[ "Patients", "undergoing", "urologic", "surgery", ".", "\n" ]

[ "Procedure" ]

Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm

Reproduktionsmedizin.90150159.ger.abstr_task0

Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .

[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]

[ "umlsterm" ]

Embryonenschutzgesetz is an umlsterm, Forschung is an umlsterm, Embryonen is an umlsterm, Deutschland is an umlsterm, Zellen is an umlsterm, Embryo is an umlsterm, Stammzellen is an umlsterm, Embryos is an umlsterm, Embryonenschutzgesetz is an umlsterm, selbst is an umlsterm, Embryo is an umlsterm, Zellen is an umlsterm, Zellkerntransfer is an umlsterm, Eizellen is an umlsterm, Stammzellen is an umlsterm, Technik is an umlsterm, Zellen is an umlsterm, Menschen is an umlsterm, Deutschland is an umlsterm, Stammzellen is an umlsterm, Gewebe is an umlsterm, Feten is an umlsterm, Gewebeentnahme is an umlsterm, Verwendung is an umlsterm, Zellen is an umlsterm, Gewebe is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Deutschland is an umlsterm, Standards is an umlsterm, Lebenswerten is an umlsterm, Gesundheit is an umlsterm, Forschung is an umlsterm, Stammzellen is an umlsterm, Stammzellen is an umlsterm, Eizellen is an umlsterm, Embryonen is an umlsterm, Klonen is an umlsterm, Menschen is an umlsterm, Menschen is an umlsterm, Stammzellen is an umlsterm

Reproduktionsmedizin.90150159.ger.abstr_task1

Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please typing these entity words according to sentence: Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .

[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]

[ "umlsterm" ]

Embryonenschutzgesetz, Forschung, Embryonen, Deutschland, Zellen, Embryo, Stammzellen, Embryos, Embryonenschutzgesetz, selbst, Embryo, Zellen, Zellkerntransfer, Eizellen, Stammzellen, Technik, Zellen, Menschen, Deutschland, Stammzellen, Gewebe, Feten, Gewebeentnahme, Verwendung, Zellen, Gewebe, Forschung, Stammzellen, Deutschland, Standards, Lebenswerten, Gesundheit, Forschung, Stammzellen, Stammzellen, Eizellen, Embryonen, Klonen, Menschen, Menschen, Stammzellen

Reproduktionsmedizin.90150159.ger.abstr_task2

Sentence: Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Embryonenschutzgesetz verbietet jegliche fremdnuetzige Forschung an und mit Embryonen . Damit ist in Deutschland die Entnahme von pluripotenten Zellen aus einem Embryo verboten . Die Gewinnung von embryonalen Stammzellen ( ES-Zellen ) aus Blastozysten erfolgt zu anderen Zwecken als zur Erhaltung des Embryos . Sie ist demgemaess nicht mit dem Embryonenschutzgesetz vereinbar . Dies gilt selbst fuer den Fall , dass der Embryo durch die Entnahme einiger Zellen in seiner Entwicklung nicht geschaedigt wuerde . Der Zellkerntransfer in entkernte Eizellen mit dem Ziel der Erzeugung von pluripotenten Stammzellen mit dem Erbgut des Zellempfaengers ist ebenfalls verboten , da mit Hilfe derselben Technik totipotente Zellen entstehen koennen , aus denen Menschen geklont werden koennten . Erlaubt ist in Deutschland die Gewinnung von pluripotenten Stammzellen aus dem Gewebe von fruehzeitig ausgestossenen toten , sowie aus abgetriebenen Feten . Eine solche Zell- oder Gewebeentnahme ist in den Richtlinien zur Verwendung fetaler Zellen und fetaler Gewebe der Bundesaerztekammer geregelt . Die DFG-Stellungnahme kommt zu dem Ergebnis , dass fuer die Forschung mit menschlichen pluripotenten Stammzellen derzeit kein Handlungsbedarf fuer eine Aenderung der deutschen Rechtslage besteht . Nach Ansicht der DFG steht der Meinungsbildungsprozess ueber ethische und medizinisch- biologische Fragen der Stammzellforschung in Deutschland , wie im Ausland , noch am Anfang . Die DFG schlaegt vor , dass dieser Meinungsbildungsprozess auf breiter Basis gefuehrt wird , und wird sich daran beteiligen . Gleichzeitig wird sich die DFG bemuehen , in dieser Frage auf die Entwicklung einheitlicher europaeischer Standards hinzuwirken , die auch die gebotenen Risikoabschaetzungen gegenueber fundamentalen und grundgesetzlich garantierten Lebenswerten wie der Menschenwuerde und der Gesundheit einschliessen . Grundsaetzlich muss fuer zukuenftige Forschung an und mit menschlichen Stammzellen nach Meinung der DFG in jedem Fall ausgeschlossen sein , dass sich aus menschlichen pluripotenten Stammzellen Eizellen Samenzellen oder Embryonen , entwickeln . Ausserdem muesste durch effektive Massnahmen sichergestellt sein , dass das Klonen von Menschen oder die Erzeugung von Menschen mit kuenstlich veraendertem Erbgut ausgeschlossen bleiben . Die Einrichtung einer zentralen Kommission , die Forschungsvorhaben mit Stammzellen nach ethischen , rechtlichen und wissenschaftlichen Gesichtspunkten beurteilt und ihre Durchfuehrung ueberwacht und begleitet , waere ein konsequenter Weg .

[ "Das", "Embryonenschutzgesetz", "verbietet", "jegliche", "fremdnuetzige", "Forschung", "an", "und", "mit", "Embryonen", ".", "Damit", "ist", "in", "Deutschland", "die", "Entnahme", "von", "pluripotenten", "Zellen", "aus", "einem", "Embryo", "verboten", ".", "Die", "Gewinnung", "von", "embryonalen", "Stammzellen", "(", "ES", "-", "Zellen", ")", "aus", "Blastozysten", "erfolgt", "zu", "anderen", "Zwecken", "als", "zur", "Erhaltung", "des", "Embryos", ".", "Sie", "ist", "demgemaess", "nicht", "mit", "dem", "Embryonenschutzgesetz", "vereinbar", ".", "Dies", "gilt", "selbst", "fuer", "den", "Fall", ",", "dass", "der", "Embryo", "durch", "die", "Entnahme", "einiger", "Zellen", "in", "seiner", "Entwicklung", "nicht", "geschaedigt", "wuerde", ".", "Der", "Zellkerntransfer", "in", "entkernte", "Eizellen", "mit", "dem", "Ziel", "der", "Erzeugung", "von", "pluripotenten", "Stammzellen", "mit", "dem", "Erbgut", "des", "Zellempfaengers", "ist", "ebenfalls", "verboten", ",", "da", "mit", "Hilfe", "derselben", "Technik", "totipotente", "Zellen", "entstehen", "koennen", ",", "aus", "denen", "Menschen", "geklont", "werden", "koennten", ".", "Erlaubt", "ist", "in", "Deutschland", "die", "Gewinnung", "von", "pluripotenten", "Stammzellen", "aus", "dem", "Gewebe", "von", "fruehzeitig", "ausgestossenen", "toten", ",", "sowie", "aus", "abgetriebenen", "Feten", ".", "Eine", "solche", "Zell-", "oder", "Gewebeentnahme", "ist", "in", "den", "Richtlinien", "zur", "Verwendung", "fetaler", "Zellen", "und", "fetaler", "Gewebe", "der", "Bundesaerztekammer", "geregelt", ".", "Die", "DFG", "-", "Stellungnahme", "kommt", "zu", "dem", "Ergebnis", ",", "dass", "fuer", "die", "Forschung", "mit", "menschlichen", "pluripotenten", "Stammzellen", "derzeit", "kein", "Handlungsbedarf", "fuer", "eine", "Aenderung", "der", "deutschen", "Rechtslage", "besteht", ".", "Nach", "Ansicht", "der", "DFG", "steht", "der", "Meinungsbildungsprozess", "ueber", "ethische", "und", "medizinisch-", "biologische", "Fragen", "der", "Stammzellforschung", "in", "Deutschland", ",", "wie", "im", "Ausland", ",", "noch", "am", "Anfang", ".", "Die", "DFG", "schlaegt", "vor", ",", "dass", "dieser", "Meinungsbildungsprozess", "auf", "breiter", "Basis", "gefuehrt", "wird", ",", "und", "wird", "sich", "daran", "beteiligen", ".", "Gleichzeitig", "wird", "sich", "die", "DFG", "bemuehen", ",", "in", "dieser", "Frage", "auf", "die", "Entwicklung", "einheitlicher", "europaeischer", "Standards", "hinzuwirken", ",", "die", "auch", "die", "gebotenen", "Risikoabschaetzungen", "gegenueber", "fundamentalen", "und", "grundgesetzlich", "garantierten", "Lebenswerten", "wie", "der", "Menschenwuerde", "und", "der", "Gesundheit", "einschliessen", ".", "Grundsaetzlich", "muss", "fuer", "zukuenftige", "Forschung", "an", "und", "mit", "menschlichen", "Stammzellen", "nach", "Meinung", "der", "DFG", "in", "jedem", "Fall", "ausgeschlossen", "sein", ",", "dass", "sich", "aus", "menschlichen", "pluripotenten", "Stammzellen", "Eizellen", "Samenzellen", "oder", "Embryonen", ",", "entwickeln", ".", "Ausserdem", "muesste", "durch", "effektive", "Massnahmen", "sichergestellt", "sein", ",", "dass", "das", "Klonen", "von", "Menschen", "oder", "die", "Erzeugung", "von", "Menschen", "mit", "kuenstlich", "veraendertem", "Erbgut", "ausgeschlossen", "bleiben", ".", "Die", "Einrichtung", "einer", "zentralen", "Kommission", ",", "die", "Forschungsvorhaben", "mit", "Stammzellen", "nach", "ethischen", ",", "rechtlichen", "und", "wissenschaftlichen", "Gesichtspunkten", "beurteilt", "und", "ihre", "Durchfuehrung", "ueberwacht", "und", "begleitet", ",", "waere", "ein", "konsequenter", "Weg", "." ]

[ "umlsterm" ]

neurotoxicity is a ADVERSE

example-381_task0

Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]

Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.

[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]

[ "ADVERSE" ]

neurotoxicity is a ADVERSE

example-381_task1

Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please typing these entity words according to sentence: neurotoxicity Options: ADVERSE

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]

Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.

[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]

[ "ADVERSE" ]

neurotoxicity

example-381_task2

Sentence: Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-ADVERSE", "O" ]

Evidence for altered hippocampal volume and brain metabolites in workers occupationally exposed to lead: a study by magnetic resonance imaging and (1)H magnetic resonance spectroscopy. Environmental and occupational exposure to lead (Pb) remains to be a major public health issue. The purpose of this cross-sectional study was to use non-invasive magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy ((1)H MRS) techniques to investigate whether chronic exposure to Pb in an occupational setting altered brain structure and function of Pb-exposed workers. The Pb-exposed group consisted of 15 workers recruited from either a Pb-smelting factory or a Pb-battery manufacturer. The control group had 19 healthy volunteers who had no history of Pb exposure in working environment or at home. The average airborne Pb concentrations in fume and dust were 0.43 and 0.44 mg/m(3), respectively, in the smeltery, and 0.10 and 1.06 mg/m(3), respectively, in the Pb battery workshop. The average blood Pb concentrations (BPb) in Pb-exposed and control workers were 63.5 and 8.7 microg/dL, respectively. The MRI examination showed that brain hippocampal volume among Pb-exposed workers was significantly diminished in comparison to age-matched control subjects (p < 0.01), although the extent of this reduction was relatively small (5-6% of the control values). Linear regression analyses revealed significant inverse associations between BPb and the decreased hippocampal volume on both sides of brain hemisphere. Among five brain metabolites investigated by MRS, i.e., N-acetyl-aspartate (NAA), creatine (Cr), choline (Cho), inosine (mI), glutamate/glutamine (Glx) and lipids (Lip), a significant decrease in NAA/Cr ratio (7% of controls, p < 0.05) and a remarkable increase in Lip/Cr ratio (40%, p < 0.01) were observed in the brains of Pb-exposed workers as compared to controls. Furthermore, the increased Lip/Cr ratio was significantly associated with BPb (r = 0.46, p < 0.01). Taken together, this study suggests that occupational exposure to Pb may cause subtle structural and functional alteration in human brains. The MRI and MRS brain imaging techniques can be used as the non-invasive means to evaluate Pb-induced neurotoxicity.

[ "Evidence", "for", "altered", "hippocampal", "volume", "and", "brain", "metabolites", "in", "workers", "occupationally", "exposed", "to", "lead", ":", "a", "study", "by", "magnetic", "resonance", "imaging", "and", "(", "1)H", "magnetic", "resonance", "spectroscopy", ".", " ", "Environmental", "and", "occupational", "exposure", "to", "lead", "(", "Pb", ")", "remains", "to", "be", "a", "major", "public", "health", "issue", ".", "The", "purpose", "of", "this", "cross", "-", "sectional", "study", "was", "to", "use", "non", "-", "invasive", "magnetic", "resonance", "imaging", "(", "MRI", ")", "and", "proton", "magnetic", "resonance", "spectroscopy", "(", "(", "1)H", "MRS", ")", "techniques", "to", "investigate", "whether", "chronic", "exposure", "to", "Pb", "in", "an", "occupational", "setting", "altered", "brain", "structure", "and", "function", "of", "Pb", "-", "exposed", "workers", ".", "The", "Pb", "-", "exposed", "group", "consisted", "of", "15", "workers", "recruited", "from", "either", "a", "Pb", "-", "smelting", "factory", "or", "a", "Pb", "-", "battery", "manufacturer", ".", "The", "control", "group", "had", "19", "healthy", "volunteers", "who", "had", "no", "history", "of", "Pb", "exposure", "in", "working", "environment", "or", "at", "home", ".", "The", "average", "airborne", "Pb", "concentrations", "in", "fume", "and", "dust", "were", "0.43", "and", "0.44", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "smeltery", ",", "and", "0.10", "and", "1.06", "mg", "/", "m(3", ")", ",", "respectively", ",", "in", "the", "Pb", "battery", "workshop", ".", "The", "average", "blood", "Pb", "concentrations", "(", "BPb", ")", "in", "Pb", "-", "exposed", "and", "control", "workers", "were", "63.5", "and", "8.7", "microg", "/", "dL", ",", "respectively", ".", "The", "MRI", "examination", "showed", "that", "brain", "hippocampal", "volume", "among", "Pb", "-", "exposed", "workers", "was", "significantly", "diminished", "in", "comparison", "to", "age", "-", "matched", "control", "subjects", "(", "p", "<", "0.01", ")", ",", "although", "the", "extent", "of", "this", "reduction", "was", "relatively", "small", "(", "5", "-", "6", "%", "of", "the", "control", "values", ")", ".", "Linear", "regression", "analyses", "revealed", "significant", "inverse", "associations", "between", "BPb", "and", "the", "decreased", "hippocampal", "volume", "on", "both", "sides", "of", "brain", "hemisphere", ".", "Among", "five", "brain", "metabolites", "investigated", "by", "MRS", ",", "i.e", ".", ",", "N", "-", "acetyl", "-", "aspartate", "(", "NAA", ")", ",", "creatine", "(", "Cr", ")", ",", "choline", "(", "Cho", ")", ",", "inosine", "(", "mI", ")", ",", "glutamate", "/", "glutamine", "(", "Glx", ")", "and", "lipids", "(", "Lip", ")", ",", "a", "significant", "decrease", "in", "NAA", "/", "Cr", "ratio", "(", "7", "%", "of", "controls", ",", "p", "<", "0.05", ")", "and", "a", "remarkable", "increase", "in", "Lip", "/", "Cr", "ratio", "(", "40", "%", ",", "p", "<", "0.01", ")", "were", "observed", "in", "the", "brains", "of", "Pb", "-", "exposed", "workers", "as", "compared", "to", "controls", ".", "Furthermore", ",", "the", "increased", "Lip", "/", "Cr", "ratio", "was", "significantly", "associated", "with", "BPb", "(", "r", "=", "0.46", ",", "p", "<", "0.01", ")", ".", "Taken", "together", ",", "this", "study", "suggests", "that", "occupational", "exposure", "to", "Pb", "may", "cause", "subtle", "structural", "and", "functional", "alteration", "in", "human", "brains", ".", "The", "MRI", "and", "MRS", "brain", "imaging", "techniques", "can", "be", "used", "as", "the", "non", "-", "invasive", "means", "to", "evaluate", "Pb", "-", "induced", "neurotoxicity", "." ]

[ "ADVERSE" ]

alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay

1.0alpha7.train.1055_task0

Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: assay, DNA, reagent, protein

[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).

[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]

[ "reagent", "DNA", "assay", "protein" ]

alpha - UBF antibody is a reagent, UBF is a protein, rDNA is a DNA, FISH is an assay

1.0alpha7.train.1055_task1

Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please typing these entity words according to sentence: alpha - UBF antibody, UBF, rDNA, FISH Options: assay, DNA, reagent, protein

[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).

[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]

[ "reagent", "DNA", "assay", "protein" ]

alpha - UBF antibody, UBF, rDNA, FISH

1.0alpha7.train.1055_task2

Sentence: To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-reagent", "I-reagent", "I-reagent", "I-reagent", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "B-assay", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

To demonstrate that the alpha-UBF antibody used here can specifically recognize UBF bound to rDNA, we performed combined immunofluorescence and FISH analysis of metaphase chromosomes isolated from Xenopus cells (Fig. 2).

[ "To", "demonstrate", "that", "the", "alpha", "-", "UBF", "antibody", "used", "here", "can", "specifically", "recognize", " ", "UBF", "bound", "to", " ", "rDNA", ",", "we", "performed", "combined", "immunofluorescence", "and", " ", "FISH", "analysis", "of", "metaphase", "chromosomes", "isolated", "from", " ", "Xenopus", "cells", "(", "Fig", ".", " ", "2", ")", "." ]

[ "reagent", "DNA", "assay", "protein" ]

Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region

62654_task0

Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_family_or_group, DNA_domain_or_region

[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]

Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.

[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]

[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]

Sp family members is a protein_family_or_group, promoter proximal repeat is a DNA_domain_or_region, HTLV - I enhancer is a DNA_domain_or_region

62654_task1

Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please typing these entity words according to sentence: Sp family members, promoter proximal repeat, HTLV - I enhancer Options: protein_family_or_group, DNA_domain_or_region

[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]

Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.

[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]

[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]

Sp family members, promoter proximal repeat, HTLV - I enhancer

62654_task2

Sentence: Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer. Instructions: please extract entity words from the input sentence

[ "B-protein_family_or_group", "I-protein_family_or_group", "I-protein_family_or_group", "O", "O", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O", "O", "B-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "I-DNA_domain_or_region", "O" ]

Sp family members preferentially interact with the promoter proximal repeat within the HTLV-I enhancer.

[ "Sp", "family", "members", "preferentially", "interact", "with", "the", "promoter", "proximal", "repeat", "within", "the", "HTLV", "-", "I", "enhancer", "." ]

[ "cell_type", "other_name", "(AND polynucleotide polynucleotide)", "virus", "DNA_domain_or_region", "", "cell_line", "protein_family_or_group", "protein_complex", "(AND other_name other_name)", "protein_molecule" ]

Datasets:

bio-datasets
/

bigbio-ner-merged

Dataset Card for "bigbio-ner-merged"